Loading menu...
Prostate cancer is the second leading cause of cancer deaths among US men  Over 200,000 new patients are diagnosed with prostate cancer every year in the US alone  About 35,000 of these men have advanced metatstatic prostate tumor for whom there is no cure 

Prostate Cancer
Colby Mission
Drug Pipeline

Pipeline

Platform

OSM-ChemGen, Oxidative Stress Chemical Genomics Platform Technology 

Colby has conducted research on OS metabolic sources and analyzed multiple pathways affected by Reactive Oxygen Species (ROS) in prostate and other diseases. Colby Scientists and collaborators developed and enabled OSM drugs filling the Colby drug pipeline. Colby is using this platform technology to identify, develop and commercialize therapeutic drugs for treatment and prevention of OS-induced prostate and other diseases, with special emphasis on prostate cancer.

 

More information on the OSM-ChemGen Technology is available upon request.